Company Risk Profile And Investor ConcernsIt will likely be difficult for investors to own this stock for some time.
Market CompetitionWith now a path for generics to enter the market, a substantial decline in Pacira’s top and bottomline is expected, and no clear path for recovery is seen.
Patent Rulings And Legal ChallengesThe U.S. District Court for the District of New Jersey ruled that patent #11,033,495 ('495) on Exparel is invalid.